The three drug candidates to be developed with Merck belong to the class known as antibody drug conjugates (ADC) and are in various stages of clinical development for the treatment of multiple solid cancer tumors.
https://www.pharmalive.com/wp-content/uploads/2023/02/ReutersMerck2-2-2023.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-10-20 07:00:072023-10-20 09:11:29Merck signs $5.5 billion deal with Daiichi for cancer therapy development
